Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
(Empagliflozin + metformin + sitagliptin) by Chong Kun Dang Pharmaceutical for Type 2 Diabetes: Likelihood of Approval
(Empagliflozin + metformin + sitagliptin) is under clinical development by Chong Kun Dang Pharmaceutical and currently in Phase I for...
CKD-331 by Chong Kun Dang Pharmaceutical for Hyperlipidemia: Likelihood of Approval
CKD-331 is under clinical development by Chong Kun Dang Pharmaceutical and currently in Phase III for Hyperlipidemia. According to GlobalData,...
CKD-331 by Chong Kun Dang Pharmaceutical for Hypertension: Likelihood of Approval
CKD-331 is under clinical development by Chong Kun Dang Pharmaceutical and currently in Phase I for Hypertension. According to GlobalData,...
CKD-846 by Chong Kun Dang Pharmaceutical for Benign Prostatic Hyperplasia: Likelihood of Approval
CKD-846 is under clinical development by Chong Kun Dang Pharmaceutical and currently in Phase I for Benign Prostatic Hyperplasia. According...